slides · global inventory
Chart
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 78,138
Current window 64,561-64,590
Pages 2,605
Rows per page 30
Component
64,561-64,590 of 78,138
49
The slide uses a bubble chart to map clinical trials and a table to detail drug performance metrics.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
50
The slide uses a combination of a conceptual chart and a data table to demonstrate efficacy in heavily pre-treated patients.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
55
The slide uses a bar chart comparison to highlight the efficacy gap between established treatments and placebo.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
10
The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the superiority of NXC-201.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
11
The slide compares HSL (Heavy-chain-led) vs LSH (Light-chain-led) configurations using bar charts for expansion and cytotoxicity metrics.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
13
The slide uses a bar chart combined with a data table to highlight safety advantages. It includes a disclaimer about cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
16
The slide uses a longitudinal timeline comparison to highlight the superior safety and efficacy profile of NXC-201.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
17
The chart illustrates the correlation between the peak of HBI0101 cells and the subsequent drop in dFLC, a marker for AL Amyloidosis.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
19
The slide uses a grouped bar chart format to highlight clinical superiority. Includes a disclaimer about cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · ActionLoop · David Goliath1 hit
20
The slide uses a table structure to contrast patient segments and includes a bar chart visualization for patient growth.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · ActionLoop · David Goliath1 hit
21
The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · ActionLoop · David Goliath1 hit
24
Includes detailed source citations in the footer; uses color-coded bars to represent different drug therapies.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
27
Includes a comparison table of clinical outcomes (ORR/CR) between NXC-201 and competitors.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
28
The slide uses a wave-like visual to represent market segments and their associated financial opportunities.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
31
The chart uses a grouped bar structure to compare NXC-201 (green) against competitors (blue/red) across three categories: No BCMA, Yes BCMA, and Overall.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
34
The chart demonstrates deepening clinical responses over time for NXC-201 therapy.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
45
The slide uses a scatter plot to map clinical trials and a table to summarize treatment outcomes across lines of therapy.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
46
The slide presents clinical data for a small sample size (n=4) in a highly pre-treated patient population.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
57
The slide uses a serpentine process flow (1-5 left-to-right, 6-10 right-to-left).Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
60
The slide uses a bar chart to contrast the combined sales of two groups of drugs, implying a large market opportunity for TSTx.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
61
The slide uses a bar chart comparison to highlight the efficacy gap between established treatments and placebo.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
05
Clinical trial results presentation.Innoviva | Results Presentation Deck | 7 slides · Innoviva
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
06
The slide highlights that these secondary analyses were not powered for statistical significance.Innoviva | Results Presentation Deck | 7 slides · Innoviva
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
07
The slide uses a waterfall-like progression to show the transition from Tier 2 component sales to Tier 1 full system sales.Innoviz | Results Presentation Deck | 20 slides · Innoviz Technologies
Conference presentation Investor relations 1 hit
10
The slide uses a combination of a text-based pipeline summary and a donut chart to visualize market penetration.Innoviz | Results Presentation Deck | 20 slides · Innoviz Technologies
Conference presentation Investor relations Beat · Market SizingLoop · Cost Of Inaction1 hit
11
The slide uses a historical context of automotive trends to frame the current shift toward autonomy.Innoviz | Results Presentation Deck | 20 slides · Innoviz Technologies
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
17
The slide includes a dual-bar chart comparing Q3 2023 revenue against Q3 2022 (YoY) and Q2 2023 (QoQ).Innoviz | Results Presentation Deck | 20 slides · Innoviz Technologies
Conference presentation Investor relations Beat · Cash PositionLoop · Why Now1 hit
12
Non-GAAP measures. See reconciliation for GAAP to non-GAAP in Appendix. Drawings not to scale.Invitae | Results Presentation Deck | 27 slides · Invitae
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
13
The slide presents two metrics: 'Change in cash/investments' (table) and 'Ongoing cash burn' (bar chart), with detailed footnotes explaining adjustments.Invitae | Results Presentation Deck | 27 slides · Invitae
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
10
The slide uses a combination of logo-based segmentation and a grouped bar chart to illustrate portfolio composition and financial scale.Kering | Fixed Income Presentation Deck | 35 slides · Kering
Deck Investor relations Beat · Solution1 hit